Skip to main content
. 2021 Aug 24;12:701951. doi: 10.3389/fimmu.2021.701951

Figure 1.

Figure 1

Clinical characteristics (A) and the distribution (B, C) of immune checkpoint inhibitor-mediated ocular side events. (A) The clinical characteristics of common ocular irAEs in lung cancer. (B) The distribution of ocular irAEs in different therapies. (C) A summary of all reported ocular irAEs in lung cancer following treatment with ICIs.